ALISO VIEJO, Calif., May 29, 2007 (PRIME NEWSWIRE) -- SenoRx (Nasdaq:SENO), a medical device company focused on the development, manufacture and sale of an expanding range of products used to diagnose and treat breast cancer, today announced that it was named Outstanding Medical Device Company by the AeA Orange County and Inland Empire Council at the 14th Annual High-Tech Innovation Awards. The theme of the awards, "The Race to Innovate," focused on the global competitive challenges facing America today.
AeA is the largest high-tech trade association in the United States and represents all segments of the technology industry. "AeA congratulates all winners and finalists for an unprecedented year of technology innovation," said Tim Jemal, executive director of the AeA Orange County/Inland Empire Council.
Paul Lubock, Chief Technology Officer of SenoRx, accepted the award on behalf of the company at an awards ceremony that drew nearly 600 luminaries from local high-tech companies, financial and government institutions, as well as academic leaders, educators, students, investors and media affiliates.
"We are pleased to be recognized for our innovation in the development of our products," says Lubock. "Our flagship diagnostic product, the EnCor system, provides numerous technological improvements to previous minimally invasive breast biopsy systems. In addition, we are excited at the prospect that our Multi-Lumen Radiation Balloon, which just received FDA 510(k) clearance, may actually expand the balloon brachytherapy market. Certain patients are currently excluded from balloon brachytherapy because of the location of the lesion within the breast. Our multi-lumen approach addresses this issue."
About SenoRx
SenoRx (Nasdaq:SENO), which completed its initial public offering of common stock in March 2007, develops, manufactures and sells minimally invasive medical devices used by breast care specialists for the diagnosis of breast cancer. SenoRx's field sales organization serves over 1,000 breast diagnostic and treatment centers in the United States and Canada. With 17 products that have already received FDA 510(k) clearance across the continuum of breast care, SenoRx is developing additional minimally invasive products for diagnosis and treatment of breast cancer. For more information, visit the company's website at www.senorx.com.
The SenoRx, Inc. logo is available at http://www.primenewswire.com/newsroom/prs/?pkgid=3605
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Specifically, statements concerning SenoRx's ability to successfully expand the balloon market, offering a solution for patients that are not otherwise candidates for balloon therapy, are forward-looking statements within the meaning of the Safe Harbor. Forward-looking statements are based on management's current, preliminary expectations and are subject to risks and uncertainties, which may cause SenoRx's actual results to differ materially from the statements contained herein. Further information on potential risk factors that could affect SenoRx's business and its financial results are detailed in its quarterly report on Form 10-Q as filed with the Securities and Exchange Commission on May 15, 2007. Undue reliance should not be placed on forward-looking statements, which speak only as of the date they are made. SenoRx undertakes no obligation to update publicly any forward-looking statements to reflect new information, events or circumstances after the date they were made, or to reflect the occurrence of unanticipated events.